– USA, MA – Cellanyx today announced the appointment of Nilesh Patel to its board of directors.
“Nilesh is an early investor in Cellanyx and shares its vision of developing novel cancer tests based on live tumor cell analysis and advanced AI technologies to enhance clinical decision making,” said Executive Chairman, Dr. Pravin Chaturvedi. “We look forward to his strategic input as Cellanyx advances its lead test for prostate cancer risk stratification towards commercialization and develops other tests in its pipeline.”
About Nilesh Patel
Nilesh is a private equity executive with an extensive background in strategy, operations, analytics, and corporate finance. His experience includes senior positions at Devonshire Investors and IBM, and most recently, running CFC – a fintech firm.
Prior to CFC, Nilesh was VP, strategy & portfolio development at Devonshire Investors – the private equity arm of Fidelity Investments. At Devonshire, Nilesh drove investment strategy and operational improvement for select portfolio companies. He joined Devonshire Investors (then Fidelity Capital) in 2006 and has managed multiple acquisition and portfolio initiatives. He also led the advanced analytics group at Devonshire, advising portfolio companies on data-driven decision making and growth strategies.
Before joining Devonshire, Nilesh was Financial Strategist at IBM Corporate Headquarters, involved in investment realignments and acquisition/divestiture projects. He has worked at Booz Allen Hamilton on healthcare and pharma manufacturing engagements. Apart from finance/investment roles, Nilesh has designed & developed several technology solutions, including engineering software at Aspen Technology.
Nilesh received a Bachelor of Technology from the Indian Institute of Technology, Mumbai, and an MBA from the Columbia Business School.
About Cellanyx
Cellanyx is developing a proprietary, living cell phenotypic cancer testing platform to aid clinical decision-making. The company technology provides quantitative, actionable assessments of individual cancer cells in biopsy samples using multiple phenotypic biochemical and biophysical markers of tumor aggressiveness and metastatic potential. Cellanyx has demonstrated clinical proof-of-concept with its lead test in development, a test to improve risk stratification in men with prostate cancer.
For more information: https://cellanyx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
